Melinta Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Melinta Therapeutics's estimated annual revenue is currently $38.8M per year.
- Melinta Therapeutics's estimated revenue per employee is $193,750
- Melinta Therapeutics's total funding is $877.4M.
Employee Data
- Melinta Therapeutics has 200 Employees.
- Melinta Therapeutics grew their employee count by 12% last year.
Melinta Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Market Access & Trade | Reveal Email/Phone |
2 | VP, Anti-Fungal Marketing | Reveal Email/Phone |
3 | VP, Manufacturing and Supply | Reveal Email/Phone |
4 | VP Drug Development | Reveal Email/Phone |
5 | VP, Commercial Strategy & Operations | Reveal Email/Phone |
6 | VP Anti-Infective Marketing | Reveal Email/Phone |
7 | Head Digital Marketing | Reveal Email/Phone |
8 | VP, Medical Affairs | Reveal Email/Phone |
9 | Head Financial Planning and Analysis | Reveal Email/Phone |
10 | VP Marketing | Reveal Email/Phone |
Melinta Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Melinta Therapeutics?
Melinta Therapeutics, Inc. (MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela® (delafloxacin), Vabomere® (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. This portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.
keywords:N/A
$877.4M
Total Funding
200
Number of Employees
$38.8M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Melinta Therapeutics News
Abbott; Allergan; Antares Pharma; Asieris Pharmaceuticals ... Johnson & Johnson Services, Inc. Melinta Therapeutics Inc. Merck & Co., Inc.
Key Chlamydia companies such as Evofem Biosciences, QureTechBio, Vault Pharma, Aeterna Zentaris, Melinta Therapeutics, Abera Bioscience,...
Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses.
Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that was launched in July. The Centers for Medicare & Medicaid S ...
MORRISTOWN, N.J.--(BUSINESS WIRE)--Mar 15, 2021-- Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin) for the t ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $54.1M | 200 | -5% | N/A |
#2 | $39.6M | 200 | 6% | N/A |
#3 | $53.9M | 200 | 6% | N/A |
#4 | $67.1M | 200 | N/A | N/A |
#5 | $46.2M | 200 | N/A | N/A |